<DOC>
	<DOC>NCT02974179</DOC>
	<brief_summary>Subjects from the AG-CLI-0206 phase 3 study that received AMG0001 will be eligible for the AG-CLI-0206-LTFU study</brief_summary>
	<brief_title>A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia</brief_title>
	<detailed_description>The study is designed to assess the long term safety of subjects who have been treated in the phase 3 study with AMG0001. A health questionnaire will be used to collect specific information from the subject every 6 months. Only those subjects that were randomized in the AG-CLI-0206 study and who received AMG0001 are eligible to participate in this long term follow-up study. Subjects that received placebo will not be eligible for participation in this study.</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Subjects who have been treated with AMG0001 in the AGCLI0206 study. Subjects who have provided consent for this long term followup study either directly or through a legally authorized representative. Subjects who have provided a release of information to the sponsor. Subjects who were not enrolled in the AGCLI0206 study. Subjects who enrolled in AGCLI0206 and who were not treated with AMG0001. Subjects who have not provided consent to this long term followup study either directly or through a legally authorized representative. Subjects who have not provided a release of information for the Sponsor to contact them directly via phone, email and/or mail.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>